SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

SANTA CRUZ BIOTECHNOLOGY, INC.

FXR2 (h2): 293T Lysate: sc-116393

BACKGROUND

Fragile X syndrome is the most frequent form of inherited mental retardation and is the result of transcriptional silencing of the FMR1 gene on the X chromosome. The FMR1 gene contains a distinct CpG dinucleotide repeat located in the 5' untranslated region of the gene, and in the fragile X syndrome this tandem repeat is substantially amplified and subjected to extensive methylation and enhanced transcriptional silencing. The FMR1 protein (or FMRP) is an RNA-binding protein that associates with polyribosomes and is a likely component of a messenger ribonuclear protein (mRNP) particle. It contains several features that are characteristics of RNA-binding proteins, including two hnRNPK homology (KH) domains and an RGG amino acid motif (RGG box). FMR1 can also interact with two fragile X syndrome related factors, FXR1 and FXR2, and these proteins form heterodimers through their N-terminal coil-coiled domains. FMR1 localizes to both the nucleus and the cytoplasm, and since it contains both a nuclear localization signal and a nuclear export signal it is also implicated in the nucleo-cytoplasmic transport of mRNAs.

REFERENCES

1. Verkerk, A.J., et al. 1991. Identification of a gene (FMR1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65: 905-914.
2. Pieretti, M., et al. 1991. Absence of expression of the FMR1 gene in fragile X syndrome. Cell 66: 817-22.
3. Matunis, M.J., et al. 1992. Characterization and primary structure of the poly(C)-binding heterogeneous nuclear ribonucleoprotein complex K protein. Mol. Cell. Biol. 12: 164-171.
4. De Boulle, K., et al. 1993. A point mutation in the FMR1 gene associated with fragile X mental retardation. Nat. Genet. 3: 31-35.
5. Zhang, Y., et al. 1995. The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. EMBO J. 14: 5358-5366.
6. Eberhart, D.E., et al. 1996. The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum. Mol. Genet. 5: 1083-1091.
7. Ceman, S., et al. 1999. Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex. Mol. Cell. Biol. 19: 7925-7932.

CHROMOSOMAL LOCATION

Genetic locus: FXR2 (human) mapping to 17p13.1.

PRODUCT

FXR2 (h2): 293T Lysate represents a lysate of human FXR2 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

APPLICATIONS

FXR2 (h2): 293T Lysate is suitable as a Western Blotting positive control for human reactive FXR2 antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

FXR2 (1G2): sc-32266 is recommended as a positive control antibody for Western Blot analysis of enhanced human FXR2 expression in FXR2 transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



FXR2 (1G2): sc-32266. Western blot analysis of FXR2 expression in non-transfected: sc-117752 (**A**) and human FXR2 transfected: sc-116393 (**B**) 293T whole cell lysates.



FXR2 (A42): sc-56681. Western blot analysis of FXR2 expression in non-transfected: sc-117752 (**A**) and human FXR2 transfected: sc-116393 (**B**) 293T whole cell lysates.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.